BACKGROUND: Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes. METHODS: A dual-centre retrospective study was performed on patients receiving ICI for melanoma, NSCLC or urothelial cancer from 2012 to 2018. Demographics, clinical data, endoscopies (reanalysed using Mayo/Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scores), histology (scored with Nancy Index) and treatment outcomes were analysed. RESULTS: In all, 1074 patients were analysed. Twelve percent (134) developed irAE colitis. Median patient age was 66, 59% were male. CTCAE diarrhoea grade does not correlate with steroid/ infliximab use. G3/4 colitis patients are more likely to need infliximab (p grade 1 CTCAE disease, and demonstrate the potential prognostic utility of objective histologic scoring.
Journal article
Br J Cancer
07/2020
123
207 - 215
Aged, Carcinoma, Non-Small-Cell Lung, Colitis, Colonoscopy, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Immune Checkpoint Inhibitors, Infliximab, Male, Melanoma, Middle Aged, Prognosis, Severity of Illness Index, Treatment Outcome, Urothelium